Monoclonal antibodies (mAbs) are immunoglobulin molecules that recognize a single epitope on a target antigen. They are typically derived from a single B-cell clone and exhibit uniform specificity and function. The standard therapeutic format is the IgG isotype, composed of two identical heavy chains and two identical light chains, with variable regions conferring antigen recognition and an Fc region mediating immune effector functions.
Bispecific antibodies (bsAbs) are next-generation mAbs. They are engineered proteins capable of binding two different epitopes or antigens simultaneously. This dual binding can occur either on the same antigen (biparatopic bsAbs) or on two distinct targets. The dual-action mechanism allows a single therapeutic molecule to modulate two biological pathways or bring two cell types into proximity, enabling complex therapeutic effects such as simultaneous pathway blockade or immune cell redirection. Compared to combination therapy using two separate mAbs, bsAbs reduce the treatment burden and may mitigate dose-limiting toxicities or drug–drug interactions.1
BsAbs are structurally diverse and broadly categorized into:
Fc-based formats (IgG-like and IgG-appended): Preserve the Fc region, conferring IgG-like stability, FcRn-mediated half-life extension, and the potential for Fc-mediated effector functions such as ADCC and CDC.
Fragment-based formats (IgG-less): Smaller, Fc-free constructs such as BiTE (bispecific T-cell engager), DART (dual-affinity retargeting), and TandAb (tandem diabody). These offer improved tissue penetration but generally have shorter serum half-lives.
Valency varies by format. Common configurations include:
1+1 format: One binding site for each target antigen.
1+2 format: One site for one antigen and two sites for the other.
2+2 format (tetravalent): Two binding sites for each antigen.
Monoclonal antibodies share a common set of mechanisms that underpin their therapeutic activity.
1. Antigen Neutralization
They can block ligand–receptor interactions by binding directly to a soluble or membrane-bound target, preventing activation of downstream signaling pathways. This may occur through competitive inhibition, steric hindrance of receptor dimerization, or conformational stabilization in an inactive state.
2. Fc-Mediated Effector Functions
Through the Fc region, mAbs recruit immune effector mechanisms such as antibody-dependent cellular cytotoxicity (ADCC) via NK cells, complement-dependent cytotoxicity (CDC) via C1q binding, and antibody-dependent cellular phagocytosis (ADCP) via macrophages.
3. Receptor Modulation
mAbs can induce internalization and degradation of receptors or lock them in inactive conformations, thereby attenuating signaling. In some cases, they may act as agonists, mimicking natural ligands to activate signaling pathways.
Bispecific antibodies retain all the fundamental mechanisms of monoclonal antibodies, including antigen neutralization, Fc-mediated effector functions, and receptor modulation, while adding capabilities enabled by their dual specificity.2,3
1. Combined Antigen Engagement
By binding two distinct epitopes, either on the same antigen (biparatopic) or on two different antigens, bsAbs can achieve additive or synergistic effects, such as more complete receptor blockade or simultaneous interference with multiple signaling pathways.
2. Immune Cell Redirection
Some bsAbs bridge immune effector cells and target cells. T-cell engagers (e.g., blinatumomab) link CD3 on T cells with a tumor-associated antigen to trigger cytotoxic activity, while NK cell engagers (BiKEs, TriKEs) direct NK-mediated killing, sometimes with cytokine domains to enhance activation.
3. Dual Checkpoint Inhibition
BsAbs can block two inhibitory immune checkpoint pathways at once (e.g., PD-L1 × CTLA-4), reducing immune suppression within the tumor microenvironment and potentially limiting adaptive resistance seen with single checkpoint blockade.
4. Dual Pathway Blockade and Biparatopic Targeting
By targeting two different receptors or two separate epitopes on the same receptor, bsAbs can prevent compensatory signaling and promote receptor internalization or degradation, improving the durability of the antitumor effect.
5. Conditional Activation
Some bsAb formats incorporate affinity tuning or protease-cleavable masks so that the molecule is functionally active only when both targets are present, reducing on-target off-tumor toxicity.
Related: Bispecific Antibody Production
mAbs benefit from mature CHO-based manufacturing processes with high yield, predictable folding, and well-characterized glycosylation profiles. Biointron uses mammalian cell platforms such as CHO-K1 and HEK293 to deliver high yields, consistent quality, and human-compatible post-translational modifications.
For bispecific antibodies, Biointron can apply advanced pairing strategies, including knob-into-hole or CrossMab. Fc engineering options allow customization of effector functions or half-life.
Purification workflows combine Protein A chromatography with orthogonal polishing to achieve high purity, and processes are designed for seamless scaling from research-grade to preclinical quantities. These capabilities enable rapid, high-quality delivery of both monoclonal and bispecific antibodies for downstream development.
Despite their therapeutic promise, the clinical translation of bispecific antibodies has progressed more slowly than that of monoclonal antibodies. The concept of dual-target T-cell redirection was described more than 30 years before the approval of the first bsAb, catumaxomab (2009, withdrawn in 2017 for commercial reasons). More recent oncology approvals include blinatumomab (2017) and amivantamab (2021), while emicizumab (2017) became the first bsAb approved outside oncology, for the treatment of hemophilia A.4
Several factors contribute to this slower clinical uptake compared to mAbs: incomplete understanding of biological mechanisms, poorly defined exposure–response relationships, insufficient safety margins, strategic portfolio decisions, and immunogenicity. The broader structural diversity of bsAbs relative to mAbs also increases uncertainty in pharmacokinetics (PK) and drug disposition, with some formats exhibiting unpredicted, suboptimal PK profiles that require additional empirical protein engineering.
To address PK challenges, strategies developed for mAbs are increasingly applied to bsAbs. Preclinical in vivo and in vitro physicochemical characterization-based PK developability assessments help identify candidates with favorable stability (physical, chemical, and thermal) and minimal non-specific interactions. Improvements in stability and reduced unintended binding typically enhance human exposure and support more practical dosing regimens. Integrating FcRn-binding analyses into these assessments further informs selection and engineering for prolonged half-life.
These approaches have been extended to bsAbs in formats such as IgG–extracellular domain (IgG–ECD) and IgG–single-chain variable fragment (IgG–scFv). Studies have shown that certain poor physicochemical properties can accelerate clearance via endothelial cell–mediated uptake in the liver. Engineering the structural configuration of the ECD has mitigated such aberrant PK in some bsAb designs. While these findings provide a foundation for understanding non-target-related clearance mechanisms, data remain limited. In particular, there is a need for prospective studies to define the contribution of physicochemical versus physiological factors to the peripheral clearance of different bsAb formats.
Related: Bispecific Antibody Production
As of August 2025, 15 bsAbs have FDA approval: Blinatumomab, Emicizumab, Amivantamab, Tebentafusp, Faricimab-svoa, Teclistamab, Mosunetuzumab, Epcoritamab, Glofitamab, Talquetamab, Elranatamab, Tarlatamab, Bizengri, Zanidatamab, and Linvoseltamab.
The global BsAb market is projected to grow significantly, driven by clinical successes and increasing investment in R&D. As of 2024, the market is valued at around USD 12 billion and is projected to reach USD 50 billion by 2030, driven by cancer incidence, targeted therapy adoption, and engineering advances.5
Selecting between a monoclonal and a next-generation bispecific format depends on multiple factors, including target biology, desired mechanism of action, manufacturability, and risk tolerance. While monoclonal antibodies benefit from established production pathways and predictable regulatory frameworks, bispecifics require additional engineering to address challenges such as chain pairing fidelity, stability, pharmacokinetics, and toxicity management.
Biointron supports biotechnology companies in meeting these demands by integrating antibody engineering, expression, and optimization. Using industry-standard mammalian cell systems such as CHO-K1 and HEK293, Biointron delivers high-yield, high-quality bispecific antibodies designed with any common format.
At Biointron, we are dedicated to accelerating antibody discovery, optimization, and production. Our team of experts can provide customized solutions that meet your specific research needs, including HTP Recombinant Antibody Production, Bispecific Antibody Production, Large-Scale Antibody Production, and Afucosylated Antibody Expression. Contact us to learn more about our services and how we can help accelerate your research and drug development projects.
Herrera, M., Giulia Pretelli, Desai, J., Garralda, E., Siu, L. L., Steiner, T. M., & Au, L. (2024). Bispecific antibodies: advancing precision oncology. Trends in Cancer, 10(10), 893–919. https://doi.org/10.1016/j.trecan.2024.07.002
The Antibody Society. Therapeutic monoclonal antibodies approved or in regulatory review. (date accessed); www.antibodysociety.org/antibody-therapeutics-product-data
U.S. Food and Drug Administration. (2024, Summer 2). Bispecific Antibodies: An Area of Research and Clinical Applications. U.S. Food and Drug Administration. https://www.fda.gov/drugs/spotlight-cder-science/bispecific-antibodies-area-research-and-clinical-applications
Datta-Mannan, A., Brown, R., Key, S., Cain, P., & Feng, Y. (2021). Pharmacokinetic Developability and Disposition Profiles of Bispecific Antibodies: A Case Study with Two Molecules. Antibodies, 11(1), 2. https://doi.org/10.3390/antib11010002
KuicK Research. (2025, March 17). Bispecific Antibodies Market Size Approved Bispecific Antibody Sales Price Patent Market Forecast 2030. GlobeNewswire News Room; KuicK Research. https://www.globenewswire.com/news-release/2025/03/17/3043524/0/en/Bispecific-Antibodies-Market-Size-Approved-Bispecific-Antibody-Sales-Price-Patent-Market-Forecast-2030.html
As of the end of 2025, 21 ADCs have been approved globally, with four new approv……
Antibody engineering has progressed beyond classical depletion and neutralizatio……
The 2025 Antibody Engineering & Therapeutics US (AET US) conference was held in ……
The 2025 mAbTalk Symposium by The Chinese Antibody Society was held in San Deigo……
You can also contact us on the Scientist and Science Exchange marketplaces.
